about
Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakinessGenetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomyGenomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitroOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpointsA Hidden Markov Model to estimate population mixture and allelic copy-numbers in cancers using Affymetrix SNP arrays.Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysisChallenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situ in the urinary bladder.Increased cell motility and invasion upon knockdown of lipolysis stimulated lipoprotein receptor (LSR) in SW780 bladder cancer cells.Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression.Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancerRisk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcriptsMicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening.Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancerEvaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs.Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer.External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancerDiagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylationComparative analysis of discrete exosome fractions obtained by differential centrifugation.Diagnostic and prognostic microRNAs in stage II colon cancer.miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors.The use of molecular analyses in voided urine for the assessment of patients with hematuria.Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomyClassification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics.Low ANXA10 expression is associated with disease aggressiveness in bladder cancerThe Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in CancerExpression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.Recent developments in molecular profiling of bladder cancer.Gene expression profiling of noninvasive primary urothelial tumours using microarrays.Recent advances in high-throughput molecular marker identification for superficial and invasive bladder cancers.The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesisChromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer.
P50
Q27303307-F3AE52B9-6F2D-4D5F-8B10-5F58B3D7849BQ28235697-EF5C3B34-1C61-4829-B9AC-72028DD28CFEQ28247046-C7DFF3A6-6FAB-4BE5-8699-110027110D51Q29617405-AE918723-34BC-422A-90D2-BA0B02587D74Q30837295-E55B5D40-D6D3-41F3-B0BF-49EDB13C116AQ31038932-83D98D81-2955-4A45-A9A0-D6D02AE7F9E3Q31138373-DAD4C539-08D6-4F07-BF0F-00AC3F853773Q33317632-9B7ABCCE-F11B-4019-A7BD-467C584BF4F9Q33353831-EE4FCE00-916B-41DC-8270-E47D49DF19E1Q33487902-6ADC462B-68FD-41D0-BB9C-E91CD0296091Q33514114-B74A8C92-02E8-47F7-9FD8-B2CF604E923FQ33670900-B71CBCDA-91A2-49A5-8095-183CD03C695AQ33721258-1D2D4238-0783-4D72-A8EE-43E7AAE26F9AQ33755486-387D113A-8BE4-45E5-B253-C1CDD8368C21Q33844958-01CA14F6-D5C7-4F7C-A1C1-75CCD16E9EB4Q33871764-65389707-324F-4DDC-A25B-C0E82F642894Q34002982-5547A95A-0AEF-491B-AD8D-ADC523563136Q34115748-8A2EDDB9-83F9-435B-A60E-DE6D3E745F1AQ34135237-CF949E30-C04D-48A3-B080-257855CB025DQ34184763-243E6829-8171-4D50-A3F5-E57406A59640Q34285082-80D95D81-F448-47C0-B8DA-7D9327D327B0Q34395643-E418CA03-E441-4E53-BABC-FFA2C4751044Q34407238-88DCD7E6-1600-4BBB-AC70-9BB23AC24791Q34441297-00F37C65-5960-4DEB-9F93-6CB221BAFD31Q34474459-D89A5F06-466D-4D26-885F-A9B013B8FDA6Q34803800-08F12D34-4586-45E8-B1B7-38BA5D4764D9Q35013059-F221EB22-D062-45EE-9428-D49EA73963BBQ35021819-5D06E1D9-B6D6-4772-BB4A-467521BE2637Q35176679-91854231-E1BB-498F-A9CC-C9F85192648AQ35443808-5392559D-684D-4E01-A8E0-9FC7B7FE3D64Q35543906-FE50032A-264C-4ECA-85FF-57C4639EFDE3Q35620687-18591859-2471-4E0C-B523-EB13397F1D91Q36022146-A9EDDCE7-842C-49F8-A210-20ED8AC9FF9BQ36075245-D6645E6C-EFCF-4DE2-A190-B37314A4E014Q36387801-D622EE2A-B11F-47CB-9532-DBA535CF4DFCQ36564700-82921BA1-6E3E-427F-BFF5-547FC57977A5Q36614918-3C0F84D6-FFCA-40AC-9B60-322E0A94D1DAQ36664746-9FE28C2A-8F4A-4BA6-BDDE-85CF36108507Q37220014-75489010-7165-4D3A-A6B3-6CFE7C421E58Q37227743-604E1CE0-DF3C-41D7-852A-A287F84F15D9
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Lars Dyrskjøt
@ast
Lars Dyrskjøt
@en
Lars Dyrskjøt
@es
Lars Dyrskjøt
@nl
Lars Dyrskjøt
@sl
type
label
Lars Dyrskjøt
@ast
Lars Dyrskjøt
@en
Lars Dyrskjøt
@es
Lars Dyrskjøt
@nl
Lars Dyrskjøt
@sl
altLabel
Lars Dyrskjøt Andersen
@en
prefLabel
Lars Dyrskjøt
@ast
Lars Dyrskjøt
@en
Lars Dyrskjøt
@es
Lars Dyrskjøt
@nl
Lars Dyrskjøt
@sl
P214
P106
P21
P214
P31
P496
0000-0001-7061-9851
P735
P7859
viaf-307229917